8-KMaterial AgreementsOther EventsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Feb 12, 2024)

Filed February 12, 2024For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) announced a significant development with the entry into a definitive Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. The acquisition will be executed through a tender offer at $32.50 per share in cash, valuing CymaBay at a total transaction value not explicitly stated in this filing but implied by the per-share offer. This strategic move aims to bolster Gilead's pipeline, particularly in areas with unmet medical needs. This transaction represents a key growth initiative for Gilead, signaling a commitment to expanding its therapeutic portfolio through targeted acquisitions. Investors should monitor the progress of the tender offer, which is subject to customary closing conditions, including regulatory approvals and a minimum tender of over 50% of CymaBay's outstanding shares. The deal includes a termination fee of $151.6 million under specific circumstances, such as CymaBay accepting a superior offer.

Key Highlights

  • 1Gilead Sciences (GILD) has entered into a merger agreement to acquire CymaBay Therapeutics, Inc.
  • 2The acquisition will be conducted via a tender offer at $32.50 per share in cash.
  • 3The transaction is structured as a merger, with a tender offer followed by a merger of equals.
  • 4Customary closing conditions apply, including antitrust review (HSR Act) and a majority tender of CymaBay shares.
  • 5CymaBay is subject to customary "no-shop" provisions, with a specified termination fee of $151.6 million under certain conditions.
  • 6The acquisition is expected to enhance Gilead's product pipeline and therapeutic offerings.
  • 7The tender offer is expected to commence shortly, with further details to be filed with the SEC.

Frequently Asked Questions

This 8-K filing announces that Gilead Sciences has entered into a material definitive agreement to acquire CymaBay Therapeutics, Inc. through a tender offer and subsequent merger.

Gilead Sciences is offering to purchase all outstanding shares of CymaBay Therapeutics for $32.50 per share in cash.

Key conditions include the tender of a number of shares representing more than 50% of CymaBay's outstanding common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, and the absence of any legal prohibitions.

CymaBay has agreed to pay Gilead a termination fee of $151,600,000 if the merger agreement is terminated under specified circumstances, such as CymaBay entering into an agreement for a superior offer.